Patents by Inventor Anne-Claude Gingras

Anne-Claude Gingras has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of modulating and antiapoptotic and antiapoptotic pathways in cells
    Publication number: 20030144190
    Abstract: More than 30% of human malignancies harbor encogenic Ras. Both pro-apoptotic and anti-apoptotic pathways emanate from encogenic Ras with survival being dominant. Ras survival signaling is thought to be controlled by transcriptional and post-translational processes. The present invention shows that a repressor of cap-dependent translation initiation, 4E-BP1, selectively activates apoptosis in Ras-transformed fibroblasts and eliminates Ras-induced chemoresistance. These effects of 4E-BP1 are strictly dependent on its ability to sequester translation initiation factor eIF4E, thereby preventing its assembly into an active pre-initiation complex. These results suggest that translational control is critical for prevention of apoptosis and resistance to antitumor agents in Ras-transformed cells.
    Type: Application
    Filed: January 8, 2003
    Publication date: July 31, 2003
    Inventors: Nahum Sonenberg, Anne-Claude Gingras, Vitaly A. Polunavsky, Peter B. Bitterman
  • Crystal of a protein-ligand complex containing an N-terminal truncated eIF4E, and methods of use thereof
    Patent number: 6020162
    Abstract: A detailed three-dimensional structure for the least abundant of the general translation initiation factors in eukaryotes, eIF4E, complexed with a ligand is disclosed. The novel N-terminal truncated eIF4Es which were constructed so as to omit a significant portion of the flexible N-terminal tail of the eIF4E are also part of the present invention. In addition, the crystals of the protein-ligand complexes containing the N-terminal truncated eIF4Es are also included. Furthermore, methods of identifying antagonists of the eIF4E protein which can be used to regulate protein synthesis in cells are also disclosed.
    Type: Grant
    Filed: June 12, 1998
    Date of Patent: February 1, 2000
    Assignees: The Rockefeller University, McGill University
    Inventors: Stephen K. Burley, Nahum Sonenberg, Joseph Marcotrigiano, Anne-Claude Gingras
  • Crystal of a protein-ligand complex containing an N-terminal truncated eIF4E, and methods of use thereof
    Patent number: 5872011
    Abstract: A detailed three-dimensional structure for the least abundant of the general translation initiation factors in eukaryotes, eIF4E, complexed with a ligand is disclosed. The novel N-terminal truncated eIF4Es which were constructed so as to omit a significant portion of the flexible N-terminal tail of the eIF4E are also part of the present invention. In addition, the crystals of the protein-ligand complexes containing the N-terminal truncated eIF4Es are also included. Furthermore, methods of identifying antagonists of the eIF4E protein which can be used to regulate protein synthesis in cells are also disclosed.
    Type: Grant
    Filed: June 13, 1997
    Date of Patent: February 16, 1999
    Assignees: The Rockefeller University, McGill University
    Inventors: Stephen K. Burley, Nahum Sonenberg, Joseph Marcotrigiano, Anne-Claude Gingras